Opthea to Host Investor Days in New York and Australia
Opthea (ASX/NASDAQ:OPT) has announced multiple investor events to discuss sozinibercept developments in wet age-related macular degeneration (wet AMD) treatment. The company will host an Investor Day in New York City on January 28, 2025, at 1:30 PM ET, followed by presentations in Sydney (February 3) and Melbourne (February 5).
The events come as Opthea anticipates topline data readouts from two pivotal trials: COAST in early CY Q2 2025 and ShORe in mid-CY 2025. The New York event will feature presentations from retina specialist Dr. Charles C. Wykoff and Chief Commercial Officer Mike Campbell, focusing on sozinibercept's potential to improve vision outcomes in wet AMD patients and commercial readiness plans when combined with anti-VEGF-A therapies.
The New York session will conclude around 3:00 PM ET and include a Q&A segment. A replay will be available on the company's website, where registration links for all events can be found under the Investor Section's 'Events and Presentations'.
Opthea (ASX/NASDAQ:OPT) ha annunciato numerosi eventi per gli investitori per discutere dello sozinibercept nel trattamento della degenerazione maculare legata all'età (AMD umida). L'azienda organizzerà un Investor Day a New York il 28 gennaio 2025, alle 13:30 ET, seguito da presentazioni a Sydney (3 febbraio) e Melbourne (5 febbraio).
Questi eventi si svolgono mentre Opthea si aspetta i dati preliminari di due studi pivotal: COAST all'inizio del secondo trimestre del 2025 e ShORe a metà del 2025. L'evento di New York presenterà relazioni dello specialista di retina Dr. Charles C. Wykoff e del Chief Commercial Officer Mike Campbell, focalizzandosi sul potenziale del sozinibercept di migliorare i risultati visivi nei pazienti con AMD umida e sui piani di prontezza commerciale quando combinato con terapie anti-VEGF-A.
La sessione di New York si concluderà intorno alle 15:00 ET e includerà un segmento di domande e risposte. Una registrazione sarà disponibile sul sito web dell'azienda, dove è possibile trovare i link per la registrazione di tutti gli eventi nella sezione 'Eventi e Presentazioni' della sezione investitori.
Opthea (ASX/NASDAQ:OPT) ha anunciado múltiples eventos para inversores para discutir desarrollos sobre sozinibercept en el tratamiento de la degeneración macular relacionada con la edad (AMD húmeda). La compañía llevará a cabo un Día del Inversor en Nueva York el 28 de enero de 2025, a la 1:30 PM ET, seguido de presentaciones en Sídney (3 de febrero) y Melbourne (5 de febrero).
Los eventos se llevan a cabo mientras Opthea anticipa los resultados iniciales de dos ensayos clave: COAST a principios del segundo trimestre de CY 2025 y ShORe a mediados de CY 2025. El evento de Nueva York contará con presentaciones del especialista en retina Dr. Charles C. Wykoff y del Director Comercial Mike Campbell, centrándose en el potencial del sozinibercept para mejorar los resultados visuales en pacientes con AMD húmeda y los planes de preparación comercial al combinarlo con terapias anti-VEGF-A.
La sesión de Nueva York concluirá alrededor de las 3:00 PM ET e incluirá una sección de preguntas y respuestas. Una repetición estará disponible en el sitio web de la compañía, donde se pueden encontrar los enlaces de registro para todos los eventos en la sección 'Eventos y Presentaciones' de la sección de inversores.
Opthea (ASX/NASDAQ:OPT)는 습기 관련 나이 관련 황반 변성을(AMD) 치료하기 위해 sozinibercept 개발에 대해 논의할 여러 투자자 이벤트를 발표했습니다. 회사는 2025년 1월 28일 오후 1시 30분 ET에 뉴욕에서 투자자 데이를 개최하고, 이어서 시드니(2월 3일) 및 멜버른(2월 5일)에서 프레젠테이션을 진행합니다.
이 이벤트는 Opthea가 두 개의 중요한 시험인 COAST(2025년 2분기 초) 및 ShORe(2025년 중반)의 탑라인 데이터 결과를 기대하고 있는 시점에서 이루어집니다. 뉴욕 행사에는 망막 전문의 Dr. Charles C. Wykoff와 최고 상업 책임자 Mike Campbell이 발표할 예정이며, 습기 AMD 환자에서 시력 개선 가능성과 항-VEGF-A 요법과 결합할 때 상업 준비 계획에 초점을 맞출 것입니다.
뉴욕 세션은 오후 3시 ET경에 종료될 예정이며, 질문 및 답변 세션이 포함됩니다. 회사 웹사이트에서 리플레이를 확인할 수 있으며, 모든 이벤트 등록 링크는 투자자 섹션의 '이벤트 및 프레젠테이션'에서 찾을 수 있습니다.
Opthea (ASX/NASDAQ:OPT) a annoncé plusieurs événements pour les investisseurs afin de discuter des progrès de sozinibercept dans le traitement de la dégénérescence maculaire liée à l'âge (AMD humide). L'entreprise organisera un Jour des Investisseurs à New York le 28 janvier 2025 à 13h30 ET, suivi de présentations à Sydney (3 février) et à Melbourne (5 février).
Ces événements surviennent alors qu'Opthea attend les résultats préliminaires de deux essais cruciaux : COAST au début du deuxième trimestre 2025 et ShORe au milieu de l'année 2025. L'événement de New York comprendra des présentations du spécialiste de la rétine Dr. Charles C. Wykoff et du directeur commercial Mike Campbell, mettant l'accent sur le potentiel de sozinibercept à améliorer les résultats visuels des patients atteints d'AMD humide et sur les plans de préparation commerciale lorsqu'il est combiné avec des thérapies anti-VEGF-A.
La session de New York se terminera vers 15h00 ET et comprendra une séance de questions-réponses. Une rediffusion sera disponible sur le site web de l'entreprise, où des liens d'inscription pour tous les événements peuvent être trouvés dans la section 'Événements et Présentations' de la section investisseurs.
Opthea (ASX/NASDAQ:OPT) hat mehrere Investorenveranstaltungen angekündigt, um die Entwicklungen von sozinibercept in der Behandlung der feuchten altersbedingten Makuladegeneration (AMD) zu erörtern. Das Unternehmen wird am 28. Januar 2025 um 13:30 Uhr ET in New York City einen Investmentag veranstalten, gefolgt von Präsentationen in Sydney (3. Februar) und Melbourne (5. Februar).
Diese Veranstaltungen finden statt, da Opthea mit den Topline-Daten von zwei entscheidenden Studien rechnet: COAST Anfang des zweiten Quartals 2025 und ShORe Mitte 2025. Die Veranstaltung in New York wird Präsentationen von dem Netzhautspezialisten Dr. Charles C. Wykoff und dem Chief Commercial Officer Mike Campbell beinhalten, die sich auf das Potenzial von sozinibercept zur Verbesserung der Sehschärfe bei Patienten mit feuchter AMD und die kommerziellen Vorbereitungspläne in Kombination mit Anti-VEGF-A-Therapien konzentrieren.
Die Sitzung in New York wird gegen 15:00 Uhr ET enden und einen Fragen-und-Antworten-Teil umfassen. Eine Wiederholung wird auf der Webseite des Unternehmens verfügbar sein, wo die Registrierungslinks für alle Veranstaltungen unter dem Abschnitt 'Veranstaltungen und Präsentationen' in der Investorenabteilung zu finden sind.
- None.
- None.
Updates on commercial insights and readiness plans for sozinibercept in wet AMD
Opthea management to present in New York City on Tuesday, January 28 at 1:30 PM ET
In-person events in Sydney on February 3 and Melbourne on February 5
MELBOURNE, Australia and PRINCETON, N.J., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that it will host an Investor Day on Tuesday, January 28, 2025 at 1:30 PM ET in New York City, followed by presentations in Sydney and Melbourne in early February.
As the Company prepares for the anticipated topline data readout of its two pivotal trials, COAST in early CY Q2 2025 and ShORe in mid-CY 2025, the New York in-person event and live webcast will feature presentations from international retina thought leader Charles C. Wykoff, MD, PhD and Opthea’s senior management team, including Chief Commercial Officer Mike Campbell. Opthea’s Investor Day will highlight the following:
- The continued medical need for better vision outcomes in wet AMD and the opportunity for sozinibercept to transform patient lives with superior vision gains.
- New insights on the commercial potential and commercial readiness plans for sozinibercept in combination with standard-of-care anti-VEGF-A therapies.
It is expected that the presentations, followed by a question-and-answer session, will conclude by approximately 3:00 PM ET. Following the live webcast, a replay will be made available on the Company’s website.
The Company’s senior management will also host in-person investor presentations in Sydney on Monday February 3 at 4:30 PM AEDT and Melbourne on Wednesday February 5 at 4:30 PM AEDT.
Links to register or access the webcast will be available on the Investor Section of the Company’s website under “Events and Presentations” here.
About Charles C. Wykoff, MD, PhD
Charles C. Wykoff, MD, PhD is a board-certified retina specialist with Retina Consultants of Texas (RCTX). Leading a top international research facility for vitreoretinal diseases, Dr. Wykoff serves as Director of Research at RCTX and is Chair of Research and Clinical Trials at Retina Consultants of America. In addition, he serves as the elected Deputy Chair of Ophthalmology for the Blanton Eye Institute, Houston Methodist Hospital, and Clinical Professor of Ophthalmology, Weill Cornell Medical College. Dr. Wykoff has been awarded multiple Achievement, Honor and Senior Honor Awards and has published over 350 peer-reviewed manuscripts. Dr. Wykoff serves as the Chief Investigator for Opthea’s COAST Phase 3 pivotal trial and is Co-Chair of the COAST and ShORe Steering Committee.
About Mike Campbell, Chief Commercial Officer, Opthea
Mr. Campbell brings 30 years of biotech and pharmaceutical commercial leadership experience across sales, marketing, market access, patient services, and operations to the Company. He dedicated most of his career to launching and commercializing innovative treatments for retinal and ocular surface diseases. During his tenure at Genentech, Mr. Campbell was a key leader for the commercial build and launch of Lucentis®, the first anti-VEGF-A treatment approved for wet AMD; he served in commercial leadership roles through the lifecycle of Lucentis®, including the expansion into Diabetic Macula Edema, and Retinal Vein Occlusion. He also contributed to the pre-launch commercial planning of Beovu® in wet AMD at Novartis, as well as the
About Opthea
Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet needs in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
Opthea’s lead product candidate, sozinibercept, is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST, NCT04757636, and ShORe, NCT04757610) for use in combination with standard-of-care anti-VEGF-A therapies to improve overall efficacy and deliver superior vision gains compared to standard-of-care anti-VEGF-A agents alone.
To learn more, visit our website at www.opthea.com and follow us on X and LinkedIn.
Authorized for release to ASX by Frederic Guerard, PharmD, CEO
| Investor Inquiries PJ Kelleher LifeSci Advisors, LLC Email: pkelleher@lifesciadvisors.com Phone: 617-430-7579 | Media Inquiries Silvana Guerci-Lena NorthStream Global Partners Email: silvana@nsgpllc.com |
Join our email database to receive program updates:
Tel: +61 (0) 3 9826 0399, Email: info@opthea.com Web: www.opthea.com
Source: Opthea Limited
FAQ
When will Opthea (OPT) release the COAST and ShORe trial results for sozinibercept?
What is the focus of Opthea's January 28, 2025 Investor Day in New York?
Where and when are Opthea's Australian investor presentations scheduled?
How can investors access Opthea's (OPT) Investor Day presentations?
Who are the key presenters at Opthea's New York Investor Day?
